Should preserving contract pharmacy arrangements be a policy priority when the evidence shows that many of these arrangements benefit large pharmacy chains and intermediaries as much—or more—than the patients Congress ultimately intended to help with 340B has created over 30 years ago?
Related Posts
Court orders HHS to restore webpages related to ‘gender ideology’
Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Last week, a U.S. district […]
Candid Health Raises $52.5M for Autonomous Revenue Cycle Automation Platform
What You Should Know: – Candid Health, a provider of autonomous revenue cycle automation solutions for healthcare providers raises $52.5M in a Series C funding […]
Seeing a Better Way for Eye Drug R&D, Character Bio Lands $93M for Two Trials in Dry AMD
A clinical trial is typically the first look at how an experimental drug works in humans. Character Biosciences is entering the clinic with a trove […]